The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -
The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.
The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.
The big pharma company's top drug is losing ground, but its dividend keeps rising.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...
Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding...
Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial...
Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong...
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.